Connect with us


Top Biotech Penny Stocks to Buy? Check These Small-Caps Out

Which biotech penny stocks are on your watchlist as Covid comes to an end?
The post Top Biotech Penny Stocks to Buy? Check These Small-Caps Out appeared first on Penny Stocks to Buy, Picks, News and Information |



3 Biotech Penny Stocks for Your June Watchlist

Biotech penny stocks have without a doubt been some of the hottest small-caps of the year. When the pandemic first hit at the beginning of 2020, most biotech companies saw their shares shoot down dramatically alongside the entire market. However, as the race for a vaccine picked up, investors witnessed major momentum among a variety of biotech penny stocks

While this began as an interest in only biotech companies focused on a Covid treatment, it quickly became an industry-wide obsession. And the result of this over a year later is an intense focus on the groundbreaking work that these companies are doing. To find the right biotech penny stock to buy, investors need to understand what to look for. The most important factor is what a company is doing and whether any of its compounds are in the commercialization stage. 

Picking the Best Biotech Penny Stocks Right Now

With biotech, the main product is either a medicine or a medical tech product. Because of the stringent process needed for approval, it can take years before a product sees approval in the U.S. or internationally. So, finding a valuable biotech penny stock is all about understanding what is in its pipeline and what has made it through the pipeline. 

[Read More] Best Penny Stocks to Buy on Robinhood Right Now? 4 To Check Out

Additionally, many biotech companies license their products out as a way to bring in additional revenue. This can result in recurring, large sums of cash on balance sheets for decades to come. Once all of this has been considered, investors should take a look at the company’s financials. 

While revenue is important, with biotech, investors tend to look at the cash balance. This indicates how long of a cash runway it has and whether it has the funds to finish any ongoing trials. With all of this in mind, let’s take a look at three biotech penny stocks for your June watchlist. 

3 Biotech Penny Stocks to Watch in 2021

  1. Sesen Bio Inc. (NASDAQ: SESN
  2. Enzolytics Inc. (OTC: ENZC)
  3. Zomedica Corp. (NYSE: ZOM)

1. Sesen Bio Inc. (NASDAQ: SESN)

Sesen Bio Inc. is a biotech penny stock that creates targeted fusion protein therapeutics for the treatment of cancer patients. It is involved in the process of design, engineering, development, and commercialization of these therapeutic products. Sesen’s lead candidate is Vicinium which is a targeted fusion protein in Phase III clinical trials to treat BCG-unresponsive non-muscle invasive bladder cancer.

It also has VB6-845d, a product candidate used to treat different anti-epithelial cell adhesion molecule solid tumors. While this may seem like a niche market, often a biotech company will become a major player in treating one or two areas of disease. And, later on, new uses can be discovered for existing compounds. 

On June 2nd, Sesen Bio made headlines after announcing a large partnership. This announcement details a new global supply partnership with Qilu Pharmaceutical. In the deal, Sesen will receive a $2 million milestone payment upon completion of a technology transfer.

Qilu will be a part of the manufacturing network for the global commercial supply of Vicineum, Sesen’s lead candidate. This is big news as manufacturing is always a concern for biotech companies. Having this partnership should help with the major commercialization efforts surrounding Vicineum.

“Qilu Pharmaceutical has extensive biomanufacturing expertise and experience supplying products for commercial sale around the world, which positions them well to support the anticipated significant global demand for Vicineum.”

The CEO and President of Sesen, Dr. Thomas Cannell

The company will also support Qilu in the development and commercialization of Vicineum in China. Now SESN stock is up more than 5% on June 7th. Will this company make your penny stocks watchlist?

2. Enzolytics Inc. (OTC: ENZC)

Another biotech penny stock showing solid market performance right now is Enzolytics Inc. ENZC is a drug development biotech company with a focus on the commercialization of its proprietary proteins. These are in use mainly to treat infectious diseases. In its product pipeline are several clinically tested and patented anti-HIV therapeutics.

It also has a proprietary cell line that produces human monoclonal antibodies, targeting and killing HIV. While research on HIV is extensive, there is still a lot of work that needs to be done on treating and curing this ailment. For that reason, many investors continue to watch ENZC stock. Considering this, what has Enzolytics been up to recently?

In the past few months, Enzolytics has made a shift into the Covid-treatment industry. On June 7th, Enzolytics released its comprehensive therapeutics protocol for the production of monoclonal antibodies. The goal is to address ongoing and future pandemics.

[Read More] Best Penny Stocks to Buy Under $5? 3 For Your Morning Watchlist

The first step of artificial intelligence in biotech is identifying conserved immutable target sites. This aspect is already complete and should help to push its pipeline further. This technique is utilized in the treatment of HIV, HTLV-1, and more recently, SARS-CoV-2 (COVID-19). As stated earlier, the pandemic has brought a lot of attention to companies both working on Covid-related treatments and those that are not. The ones that are, however, are also aiming to use the new advancements for potential future pandemics. 

After this announcement was made, ENZC stock increased by around 30% on June 7th. Now, it will be interesting to see how the company continues to advance its groundbreaking work. So, as a company with a lot in its pipeline both novel and highly researched, will ENZC stock be on your watchlist this year?


3. Zomedica Corp. (NYSE: ZOM)

Zomedica Corp. is a biotech stock that is different from the others on this list. Rather than producing compounds for humans, ZOM develops medical products for companion animals. Its main product is TRUFORMA which is a diagnostic biosensor platform that detects thyroid disorders in dogs and cats, as well as adrenal disorders in dogs. 

It currently has a collaboration agreement with Celsee Inc. to develop and commercialize liquid biopsy assays and related consumables for cancer detection in companion animals. Last month, ZOM released its first quarter financial results for 2021 which had a decent impact on its share price. 

“Our first product, TRUFORMA®, now is on the market and we are building out our direct sales organization to reach our customers; we are working hard with Qorvo Biotechnologies, our technology partner, to complete additional assays to complement the initial three that are currently available to customers; and we have cash and cash equivalents of more than $250 million to support our commercialization efforts and our product and corporate growth plans.”

The CEO of Zomedica, Robert Cohen

Zomedica is considered a “meme stock” by many traders. This is a term given to stocks that are heavily invested in by retail traders use platforms like Reddit and Twitter to find companies to invest in. This started with the popular subreddit r/WallStreetBets and since then, many new meme stocks have exploded in popularity.

Because of its frequent mentions on social media, ZOM stock can often see large price swings with no reason to back it. For this reason, the company could be seen as more of a volatile investment. With all of this information in mind, will ZOM make it on to your list of penny stocks to watch?


Which Biotech Penny Stocks Are On Your Watchlist?

Picking the best biotech penny stocks to watch is all about understanding the ebb and flow of the market. While some may have value in the short term, others could have better long-term prospects.

[Read More] Robinhood Penny Stocks Riding the AMC & Reddit Wave, Time to Hodl?

Educating yourself on how to trade penny stocks overall and those in specific industries, will always be a major asset to your portfolio. And in 2021, there is a lot to keep track of. So, considering all of this, which biotech penny stocks are on your watchlist?

The post Top Biotech Penny Stocks to Buy? Check These Small-Caps Out appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading

Spread & Containment

COVID-19 may never go away, but practical herd immunity is within reach

It is unlikely that we will reach full herd immunity for COVID-19. However, we are likely to reach a practical kind of herd immunity through vaccination.

The level of immunity needed — either through vaccination or infection — for practical herd immunity is uncertain, but may be quite high. (Shutterstock)

When people say that we won’t reach “herd immunity” to COVID-19, they are usually referring to an ideal of “full” population immunity: when so many people are immune that, most of the time, there is no community transmission.

With full herd immunity, most people will never be exposed to the virus. Even those who are not vaccinated are protected, because an introduction is so unlikely to reach them: it will sputter out, because so many others are immune — as is the case now with diseases like polio and mumps.

The fraction of the population that needs to be immune in order for the population to have “full” herd immunity depends on the transmissibility of the virus in the population, and on the control measures in place.

It is unlikely we’ll reach full herd immunity for COVID-19.

For one thing, it appears that immunity to COVID-19 acquired either by vaccination or infection wanes over time. In addition, SARS-CoV-2 will continue to evolve. Over time, variants that can infect people with immunity (even if this only results in mild disease) will have a selective advantage, just as until now selection has mainly favoured variants with higher transmission potential.

Electron micrograph of a yellow virus particle with green spikes, against a blue background.
The B.1.1.7 variant of the SARS-CoV-2 virus. Over time, variants of concern will likely continue to emerge. NIAID, CC BY

Also, our population is a composition of different communities, workplaces and environments. In some of these, transmission risk might be high enough and/or immunity low enough to allow larger outbreaks to occur, even if overall in the population we have high vaccination and low transmission.

Finally, SARS-CoV-2 can infect other animals. This means that other animal populations may act as a “reservoir,” allowing the virus to be reintroduced to the human population.

Practical herd immunity

Nonetheless, we are likely to reach a practical kind of herd immunity through vaccination. In practical herd immunity, we can reopen to near-normal levels of activity without needing widespread distancing or lockdowns. This would be a profound change from the situation we have been in for the past 18 months.

Practical herd immunity does not mean that we never see any COVID-19. It will likely be with us, just at low enough levels that we will not need to have widespread distancing measures in place to protect the health-care system.

Read more: COVID-19 variants FAQ: How did the U.K., South Africa and Brazil variants emerge? Are they more contagious? How does a virus mutate? Could there be a super-variant that evades vaccines?

What level of immunity (either through vaccination or infection) we need for practical herd immunity is uncertain, but it may be quite high. The original strain of SARS-CoV-2 was highly transmissible and transmission is thought to be higher still for some variants of concern.

Empty vials of Pfizer's COVID-19 vaccine
To achieve two-thirds immunity, 90 per cent of the eligible population would need to be vaccinated or infected naturally. (AP Photo/John Locher)

The amount of immunity we need will also depend on what level of controls we are willing to maintain indefinitely. Continued masking, contact tracing, symptomatic and asymptomatic testing and outbreak control measures will mean we will require less immunity than we would without these in place.

Some estimates suggest that we may need two thirds of the population to be protected either by successful vaccination or natural infection. If 90 per cent of the population is eligible for vaccination, and vaccines are 85 per cent effective against infection, we can obtain this two thirds with about 90 per cent of the eligible population being vaccinated or infected naturally.

The United Kingdom has already exceeded these rates in some age groups. Higher rates are even better, because there is still uncertainty about the level of transmissibility and vaccine efficacy against infection (although research shows they are very good against severe disease). We don’t want to discover that we do not have enough immunity through vaccination and have another serious wave of infection.

Emerging variants

A sticker reading 'I'm COVID-19 vaccinated' from Vancouver Coastal Health
Booster vaccinations will hopefully allow us to maintain long-term practical herd immunity against future variants of COVID-19. THE CANADIAN PRESS/Jonathan Hayward

Higher vaccine uptake will mean there are fewer infections before we reach practical herd immunity. The remaining unvaccinated individuals will be safer, protected indirectly by the immunity of those around them. Outbreaks will be smaller and rarer, and there will be fewer opportunities for vaccine escape variants to arise and spread.

That said, variants of SARS-CoV-2 will continue to emerge, and selection will favour variants that escape our immunity. Vaccine developers will continue to broaden the spectrum of the vaccines that are available, and boosters will hopefully allow us to maintain long-term practical herd immunity.

It’s possible that an immune escape variant will emerge that is severe enough, and transmissible enough, that it will cause a new pandemic for which we do not have even practical herd immunity. But barring that, while we may not be free of COVID-19, we can be confident that in the not-too-distant future it will be manageable when we return to near-normal life.

Caroline Colijn's research group receives funding from the Natural Sciences and Engineering Research Council of Canada, Genome British Columbia, the Michael Smith Foundation for Health Research, the Public Health Agency of Canada and Canada 150 Research Chair program of the Federal Government of Canada.

Paul Tupper's research group receives funding from the Natural Sciences and Engineering Research Council of Canada.

Read More

Continue Reading

Spread & Containment

UK Government Adviser Says Mask Mandates Should Continue “Forever”

UK Government Adviser Says Mask Mandates Should Continue "Forever"

Authored by Paul Joseph Watson via Summit News,

A UK government adviser and former Communist Party member Susan Michie says that mask mandates and social distancing should…



UK Government Adviser Says Mask Mandates Should Continue "Forever"

Authored by Paul Joseph Watson via Summit News,

A UK government adviser and former Communist Party member Susan Michie says that mask mandates and social distancing should continue “forever” and that people should adopt such behaviour just as they did with wearing seatbelts.

Michie, who is a Professor of Health Psychology at UCL and a leading member of SAGE, said such control measures should become part of people’s “normal” routine behaviour.

"Vaccines are a really important part of pandemic control but it is only one part. [A] test, trace and isolate system, [as well as] border controls, are really essential. And the third thing is people’s behaviour. That is, the behaviour of social distancing, of… making sure there’s good ventilation [when you’re indoors], or if there’s not, wearing face masks, and [keeping up] hand and surface hygiene."

"We will need to keep these going in the long term, and that will be good not only for Covid but also to reduce other [diseases] at a time when the NHS is [struggling]… I think forever, to some extent…"

"I think there’s lots of different behaviours that we have changed in our lives. We now routinely wear seatbelts – we didn’t use to. We now routinely pick up dog poo in the parks – we didn’t use to. When people see that there is a threat and there is something they can do to reduce that [to protect] themselves, their loved ones and their communities, what we have seen over this last year is that people do that."

Michie’s comments once again emphasize how many scientific advisers have become drunk on COVID-19 power and never want to relinquish it.

“Unsurprisingly, Channel 5 News made absolutely no effort to scrutinise these claims. The programme’s presenter raised no objection to the idea that mask-wearing and social distancing could continue “forever”, resorting only to friendly laughter,” writes Michael Curzon.

“Professor Michie’s co-panellist, a fellow scientist at UCL, Dr Shikta Das, said:

“I think Susan has made a very good point here,” adding that the vaccine roll-out has created a “false sense of security”.

She concluded:

“I don’t think we are yet ready to unlock.”

How’s all that for balance!

Perhaps unsurprisingly, Michie is known to be a long-time Communist hardliner and was so zealous in her beliefs she garnered the nickname “Stalin’s nanny.”

Her sentiment echoes that of fellow government adviser Professor Neil Ferguson, who once acknowledged that he was surprised authorities were able to “get away with” the same draconian measures that Communist China imposed at the start of the pandemic.

“[China] is a communist one-party state, we said. We couldn’t get away with [lockdown] in Europe, we thought… and then Italy did it. And we realised we could,” said Ferguson.

*  *  *

Brand new merch now available! Get it at

*  *  *

In the age of mass Silicon Valley censorship It is crucial that we stay in touch. I need you to sign up for my free newsletter here. Support my sponsor – Turbo Force – a supercharged boost of clean energy without the comedown. Also, I urgently need your financial support here.

Tyler Durden Sat, 06/12/2021 - 11:30

Read More

Continue Reading

Spread & Containment

Venezuela Says US Sanctions Blocking COVID Vaccines: ‘Global Health System’ As Geopolitical Weapon

Venezuela Says US Sanctions Blocking COVID Vaccines: ‘Global Health System’ As Geopolitical Weapon

Authored by Brett Wilkins via via,

Venezuelan Vice President Delcy Rodríguez has accused the US-backed international financia



Venezuela Says US Sanctions Blocking COVID Vaccines: 'Global Health System' As Geopolitical Weapon

Authored by Brett Wilkins via via,

Venezuelan Vice President Delcy Rodríguez has accused the US-backed international financial system of blocking the country's access to Covid-19 vaccines under the COVAX program, even though Venezuela has paid all but $10 million of the $120 million it owes.

Appearing in a televised address, Rodríguez said Venezuela was unable to pay the remaining $10 million because it was being blocked from transferring funds to the Switzerland-based GAVI Vaccine Alliance, which directs COVAX. "The financial system that also hides behind the U.S. lobby has the power to block resources that can be used to immunize the population of Venezuela," she said.

Via Reuters

Venezuelan Foreign Minister Jorge Arreaza tweeted a letter from COVAX stating that it "received notification from UBS Bank" that four payments, totaling just over $4.6 million, were "blocked and under investigation."

Arreaza said that "Venezuela has paid all of its commitments," adding that "the bank has arbitrarily blocked" the country's final payments and calling the situation "a crime."

The vice president and foreign minister's remarks follow accusations from Venezuelan President Nicolás Maduro last week that "organizations of US imperialism" are engaged in an effort to stop vaccine producers from selling doses to the country.

"Venezuela might be the only country in the world that is subject to a persecution against its right to freely purchase vaccines," said Maduro, according to Venezuelanalysis. "Venezuela is besieged so that it cannot buy vaccines."

A mural in Caracas symbolically shows Venezuela and Russia uniting to defeat the coronavirus, with the caption: "We will beat Covid-19 together." Image: AFP via Getty

Successive US administrations have targeted Venezuela with economic sanctions that critics say have devastated the nation's once-thriving economy and have caused tremendous suffering for the poor and working-class people whose dramatic uplift was once hailed as the great success of the Bolivarian Revolution launched under the late President Hugo Chávez. 

According to a 2019 report from the Center for Economic and Policy Research, a progressive think tank based in Washington, D.C., as many as 40,000 Venezuelans have died due to sanctions, which have made it much more difficult for millions of people to obtain food, medicine, and other necessities. 

Maduro also denounced the World Health Organization (WHO) for its role in delaying vaccine delivery to Venezuela. The president had expected "many millions" of the Covid-19 jabs to be delivered in July and August. "The COVAX system owes a debt to Venezuela," asserted Maduro. "We made a deposit in April and we are waiting for the vaccines."

That $64 million deposit to GAVI came after a rare deal between the Maduro administration and Juan Guaidó, the coup leader recognized by the United States and dozens of other nations as Venezuela's legitimate head of state despite never having been elected.

Adept at circumventing US interference in its affairs, Venezuela turned to China, Russia, and Cuba to launch its mass vaccination program, which aims to inoculate 70% of the population this year. Earlier this month, the country reached a deal to buy and locally manufacture the Russian EpiVacCorona vaccine. Venezuela has also already acquired about three million doses of the Russian Sputnik V and Chinese Sinopharm jabs, and last month began clinical trials on Cuba's Adbala vaccine.

Compared to other nations in the region, Venezuela has reported a very low rate of coronavirus infections and deaths. According to Johns Hopkins University's Coronavirus Resource Center, there have been nearly 248,000 reported cases and 2,781 deaths in the country of 28.5 million people during the ongoing pandemic. Neighboring Colombia, with just over 50 million people, has reported more than 3.6 million cases and over 94,000 deaths.

Tyler Durden Sat, 06/12/2021 - 16:30

Read More

Continue Reading